Physician profile
Crystal Sin
NPI 1861264723
$3,853.54
in general payments reported to CMS, 2019-2025
7 companies · $2,731 in 2025
The $2,731 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $250 · 2024: $872 · 2025: $2,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,212 · Travel and Lodging: $1,634 · Education: $7.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,212.19 |
| Travel and Lodging | $1,633.92 |
| Education | $7.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,087.76 | 2025 | Acuvue |
| Bausch & Lomb Americas INC. | $573.96 | 2023-2025 | Infuse, Miebo, Vyzulta |
| Coopervision INC. | $495.75 | 2024-2025 | Myday Contact Lens, Paragon Crt, Cvi Contact Lens |
| Alcon Vision LLC | $373.73 | 2024-2025 | Dailies Total1, Precision 1, Total30 |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Glaukos Corporation | $121.77 | 2024 | Ce-Marked Kxla System |
| Sun Pharmaceutical Industries INC. | $75.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Sin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.